
Biogen's Alzheimer's drug slows cognitive decline in midstage study, eyeing Phase 3
In a mid-stage Phase 2 trial, Biogen's experimental Alzheimer’s drug diranersen slowed cognitive decline to rates similar to approved therapies and reduced brain tau, a result that supports advancing to Phase 3 pending confirmation.





